ABSTRACT
Myofibroblastic cancer-associated fibroblast (myoCAF)-rich tumors generally contain few T cells and respond poorly to immune-checkpoint blockade. Although myoCAFs are associated with poor outcome in most solid tumors, the molecular mechanisms regulating myoCAF accumulation remain unclear, limiting the potential for therapeutic intervention. Here, we identify ataxia-telangiectasia mutated (ATM) as a central regulator of the myoCAF phenotype. Differentiating myofibroblasts in vitro and myoCAFs cultured ex vivo display activated ATM signaling, and targeting ATM genetically or pharmacologically could suppress and reverse differentiation. ATM activation was regulated by the reactive oxygen species-producing enzyme NOX4, both through DNA damage and increased oxidative stress. Targeting fibroblast ATM in vivo suppressed myoCAF-rich tumor growth, promoted intratumoral CD8 T-cell infiltration, and potentiated the response to anti-PD-1 blockade and antitumor vaccination. This work identifies a novel pathway regulating myoCAF differentiation and provides a rationale for using ATM inhibitors to overcome CAF-mediated immunotherapy resistance. SIGNIFICANCE: ATM signaling supports the differentiation of myoCAFs to suppress T-cell infiltration and antitumor immunity, supporting the potential clinical use of ATM inhibitors in combination with checkpoint inhibition in myoCAF-rich, immune-cold tumors.
Subject(s)
Ataxia Telangiectasia Mutated Proteins , Cancer-Associated Fibroblasts , Immunotherapy , Neoplasms , Humans , Ataxia Telangiectasia Mutated Proteins/metabolism , Cancer-Associated Fibroblasts/metabolism , Cell Differentiation , Myofibroblasts/metabolism , Drug Resistance, NeoplasmABSTRACT
Long non-coding RNAs (lncRNAs) are a diverse class of RNA transcripts which have limited protein coding potential. They perform a variety of cellular functions in health, but have also been implicated during malignant transformation. A further theme in recent years is the critical role of the tumour microenvironment and the dynamic interactions between cancer and stromal cells in promoting invasion and disease progression. Whereas the contribution of deregulated lncRNAs within cancer cells has received considerable attention, their significance within the tumour microenvironment is less well understood. The tumour microenvironment consists of cancer-associated stromal cells and structural extracellular components which interact with one another and with the transformed epithelium via complex extracellular signalling pathways. LncRNAs are directly and indirectly involved in tumour/stroma cross-talk and help stimulate a permissive tumour microenvironment which is more conducive for invasive tumour growth. Furthermore, lncRNAs play key roles in determining the phenotype of cancer associated stromal cells and contribute to angiogenesis and immune evasion pathways, extracellular-matrix (ECM) turnover and the response to hypoxic stress. Here we explore the multifaceted roles of lncRNAs within the tumour microenvironment and their putative pathophysiological effects.
Subject(s)
Neoplasms/genetics , Neoplasms/pathology , RNA, Long Noncoding/genetics , Stromal Cells/metabolism , Tumor Microenvironment , Disease Progression , Extracellular Matrix/metabolism , Humans , Neoplasms/blood supply , Signal Transduction , Stromal Cells/pathologyABSTRACT
The epidermis is a multi-layered stratified epithelium continuously renewed by differentiating keratinocytes that develops by the action of p63, a member of the p53 family. The TP63 contains two promoters, resulting in the expression of different proteins, containing (TAp63) or not (DeltaNp63) an amino-terminal transactivation domain, which contribution in skin formation is not fully understood. We found that p63 binds and transactivate GATA-3 promoter, which in turn transactivate IKKalpha, two pivotal regulators of epithelial development. Indeed, GATA-3 is a regulator of cell lineage in skin and hair follicles formation. To further study the relationship between GATA-3 and p63 isoforms here we investigated their expression during keratinocyte differentiation, in human epidermis and hair follicle.
Subject(s)
DNA-Binding Proteins/metabolism , Epidermis/metabolism , GATA3 Transcription Factor/metabolism , Hair Follicle/metabolism , Keratinocytes/metabolism , Trans-Activators/metabolism , Tumor Suppressor Proteins/metabolism , Antibodies/immunology , Cell Differentiation , DNA-Binding Proteins/chemistry , DNA-Binding Proteins/immunology , Humans , Keratinocytes/cytology , Trans-Activators/chemistry , Trans-Activators/immunology , Transcription Factors , Tumor Suppressor Proteins/chemistry , Tumor Suppressor Proteins/immunologyABSTRACT
Although signal transducer and activator of transcription 1 (STAT1) mediated regulation of p53 transcription and apoptosis has been previously reported, modulation of other members of the p53 family of transcription factors remains poorly understood. In this study, we found that STAT1 and TA-p73 can interact directly and that p73-mediated Bax promoter activity was observed to be reduced by STAT1 expression in a p53-independent manner for which STAT1 Tyrosine-701 and Serine-727 are key residues. This study presents the first report physically linking STAT1 and TA-p73 signalling and highlights the modulation of the Bax promoter in the context of IFN-gamma stimulation.
